Latisse®
Bimatoprost 0.03% · ophthalmic solution
Aesthetics/Presbyopia
Approved uses
Eyelash hypotrichosis
One drop on a sterile applicator applied along the skin of the upper eyelid margin at the base of the lashes, once nightly, one applicator per eye
Most see no visible change before 2 months, and lashes return to baseline after stopping.
Eyelash hypotrichosis after chemotherapy
One drop on a sterile applicator applied to the upper eyelid margin, once nightly, one applicator per eye
About 4 in 10 respond by month 4 after chemotherapy, with further gain out to 12 months.
OFF-LABELNot in the FDA label for this product
Eyebrow hypotrichosis
Bimatoprost 0.03% solution applied to each eyebrow once daily; the trial dosed daily for 9 months
Pilot RCT · n=20
Randomized, double-blind, vehicle-controlled pilot study, n=20 with mild to moderate eyebrow hypotrichosis. Investigator-assessed eyebrow appearance improved from baseline at 6 months (P=.002) and 7 months (P=.005) in the group treated for 9 months, while the group crossed to 4 months of bimatoprost was not significant at any time point and no adverse effects were observed; pilot-sized, so the estimate is imprecise.
Contraindications
Hypersensitivity to bimatoprost or any component
0.03% (0.3 mg/mL) solution, 3 mL bottle with 70 applicators, 5 mL bottle with 140 applicators
Structural prostaglandin analog. The precise mechanism is unknown; eyelash growth is believed to occur by increasing the percent of hairs in, and the duration of, the anagen or growth phase.
Warnings & Precautions
- Effects on intraocular pressure: In patients using LUMIGAN or other prostaglandin analogs for elevated IOP, concomitant use may interfere with the desired reduction in IOP; they should use it only after consulting their physician and be closely monitored for IOP changes. Exposure of the eye to more than one dose of bimatoprost daily may decrease the IOP-lowering effect. In trials, in patients with or without elevated IOP, it lowered IOP, but not by an amount of clinical concern.
- Iris pigmentation: Increased iris pigmentation has occurred; advise patients of the potential for increased brown iris pigmentation, which is likely to be permanent. The change is due to increased melanin content in the melanocytes rather than more melanocytes, and its long term effects are not known. It may not be noticeable for several months to years; typically the brown pigmentation around the pupil spreads concentrically towards the periphery. Treatment can be continued.
- Lid pigmentation: Bimatoprost has been reported to cause darkening of periorbital pigmented tissues and eyelashes; the pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation in most patients.
- Hair growth outside treatment area: Repeated skin contact beyond the upper eyelid margin can grow hair there; blot runoff before it reaches the cheek or other skin.
- Intraocular inflammation: Caution with active intraocular inflammation such as uveitis, which may be exacerbated.
- Macular edema: Macular edema, including cystoid macular edema, has been reported with bimatoprost ophthalmic solution (LUMIGAN) for elevated IOP; use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
- Contamination: Keep the bottle intact, and the bottle tip should not be allowed to contact any other surface. Use each sterile applicator on one eye only and then discard it, since reuse increases the potential for contamination and infections. Bacterial keratitis has been reported in association with the use of multiple-dose containers of topical ophthalmic products.
- Use with contact lenses: Benzalkonium chloride may be absorbed by and cause discoloration of soft contact lenses; remove lenses before application and reinsert 15 minutes after.
Common Side Effects
- Ocular, most common: Eye pruritus and conjunctival hyperemia, each approximately 3% to 4%; ocular irritation and dry eye symptoms under 4%; foreign body sensation reported without a frequency.
- Periocular skin: Skin hyperpigmentation approximately 3% to 4%; periorbital erythema under 4%; dry skin and skin exfoliation of the eyelid or periocular area postmarketing.
- Pigmentation: Iris hyperpigmentation and periorbital skin discoloration.
- Lash changes: Abnormal hair growth, madarosis, trichorrhexis, and trichiasis; disparity between eyes in length, thickness, pigmentation, number, or direction of lashes.
- Periorbital fat atrophy: Skin tightness with deepening of the eyelid sulcus and eyelid ptosis; postmarketing.
- Other ocular, postmarketing: Eye swelling, eyelid edema, hordeolum, increased lacrimation, blurred vision, local allergic reactions.
- Systemic, reported with the IOP-lowering formulation: Headache, asthenia, colds and upper respiratory infections.
Pregnancy: No adequate and well-controlled studies in pregnant women; postmarketing experience shows no increase in major birth defects or miscarriage. Oral dosing during organogenesis caused abortion and early delivery in mice and rats at oral doses at least 33 times (mice) and 94 times (rats) human exposure by AUC, and these effects were not seen at 2.6 times (mice) or 47 times (rats). In rats dosed orally from organogenesis to the end of lactation, gestation length and fetal body weight fell and fetal and pup mortality rose at oral doses at least 41 times human exposure; no adverse effects were seen in offspring at an estimated 14 times. Use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Unknown whether topical ocular use yields detectable quantities in human milk; present in rat milk at an IV dose 324 times the recommended human ophthalmic dose on a mg/m2 basis, but no animal data are available at clinically relevant doses. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breastfed child.
Evaluated in a sixteen-week vehicle-controlled study in pediatric patients 5 to 17 years who were post-chemotherapy or had alopecia areata, and in adolescents 15 to 17 years with hypotrichosis; no new safety issues were observed. At least a 1-grade GEA increase at month 4 occurred in 73% of adolescents with hypotrichosis (vehicle 7%), 85% of post-chemotherapy patients (vehicle 100%), and 44% of alopecia areata patients (vehicle 33%).